Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

KW-2450

Known as: IGF-1R/IR Inhibitor KW-2450 
An orally bioavailable inhibitor of insulin-like growth factor 1 receptor (IGF-1R) and insulin receptor (IR) tyrosine kinases with potential… Expand
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

IndazolesPiperazines
Receptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Preclinical and phase I clinical studies of KW-2450, a dual IGF-1R/IR tyrosine kinase inhibitor, in combination with lapatinib and letrozole
Background: KW-2450 is an oral dual insulin-like growth factor-1 receptor/insulin receptor tyrosine kinase inhibitor. We… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • table 2
2016
2016
Preclinical and first‐in‐human phase I studies of KW‐2450, an oral tyrosine kinase inhibitor with insulin‐like growth factor receptor‐1/insulin receptor selectivity
Numerous solid tumors overexpress or have excessively activated insulin‐like growth factor receptor‐1 (IGF‐1R). We summarize… Expand
2015
2015
Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases
Currently, no targeted drug is available for triple-negative breast cancer (TNBC), an aggressive breast cancer that does not… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 4
  • figure 5
2015
2015
Antitumor Activity of KW-2450 against Triple- NegativeBreastCancerbyInhibitingAuroraAand
Currently, no targeted drug is available for triple-negative breast cancer (TNBC), an aggressive breast cancer that does not… Expand
2013
2013
Abstract 920: KW-2450, a novel IGF-1R/IR inhibitor, enhances the antitumor effect of lapatinib, letrozole or 4-hydroxy-tamoxifen in breast cancer cells.
[Background] Both the insulin-like growth factor-1 receptor (IGF-1R) and insulin receptors (IR) have been found to be promising… Expand
2013
2013
Abstract P2-09-04: Development of novel combination therapy of IGF-1R/InsR and MEK inhibitors in triple-negative breast cancer (TNBC)
Recent studies found that TNBC had a highly activated profile in the insulin-like growth factor 1 receptor (IGF-1R)/insulin… Expand
2013
2013
Abstract 2431: IGF1R/IR axis is a novel treatment target in ER-negative breast cancer.
Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC Background/Hypothesis: Insulin growth factor-1… Expand
2011
2011
Open-label, sequential, ascending, multi-dose, phase I study of KW-2450 as monotherapy in subjects with previously treated advanced solid tumors.
3078 Background: KW-2450, a potent small molecule insulin-like growth factor receptor (IGF-1R)/insulin receptor (IR) antagonist… Expand
2011
2011
Abstract 3605: KW-2450, a novel orally-active dual IGF1R/IR inhibitor: Antitumor effects in vitro and in vivo
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL KW-2450 is an orally active, multi-kinase inhibitor… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE